What Is Precision Oncology? Personalized Cancer Treatment Explained
Precision oncology uses tumour biology and biomarkers to match patients with targeted therapies or immunotherapies. Learn how testing works, who it helps, and what to ask your cancer specialist.
सिंहावलोकन
Cancer treatment is no longer guided by tumour location alone. Precision oncology looks at the molecular features of a cancer—mutations, receptors, and other biomarkers—to choose therapies more likely to help a particular patient. Families often hear terms like targeted therapy, NGS, PD-L1, or companion diagnostics and wonder what they mean in practical terms. Here is a clear overview of how precision oncology works and when it matters.
Precision Oncology in Simple Terms
Traditional plans often started with cancer type and stage, then applied standard chemotherapy, surgery, or radiation pathways. Precision oncology adds another layer: the biology of your tumour.
Two patients with lung cancer, for example, may need completely different medicines if one has an EGFR mutation and the other has high PD-L1 expression. The diagnosis may sound the same; the treatment path may not.
This approach does not replace clinical judgement, imaging, or pathology. It helps refine choices so treatment is more tailored and, when possible, more effective with fewer unnecessary side effects.
Biomarkers and Molecular Testing
A biomarker is a measurable feature that provides information about the cancer or how it may respond to treatment. Examples include hormone receptors in breast cancer, HER2 status, EGFR or ALK changes in lung cancer, BRAF in some tumours, and MSI or PD-L1 for immunotherapy decisions.
Testing may use tissue from a biopsy or surgery. In selected cases, blood-based tests (liquid biopsy) can detect circulating tumour DNA. Your oncologist decides which tests are relevant based on cancer type, stage, and treatment goals.
Not every patient needs every test. Ordering the right panel at the right time is more useful than running unrelated investigations.
- Pathology confirmation remains the foundation
- IHC and molecular tests identify actionable targets
- NGS panels can check many genes at once when indicated
- Results guide targeted therapy or immunotherapy choices
Targeted Therapy vs Chemotherapy vs Immunotherapy
Chemotherapy attacks rapidly dividing cells more broadly. Targeted therapy focuses on specific molecular drivers that help cancer grow. Immunotherapy helps the immune system recognise and attack cancer cells, sometimes guided by biomarkers such as PD-L1 or MSI-high status.
Precision oncology often means choosing among these options—or combining them—based on evidence for your tumour profile. A targetable mutation may open a tablet-based targeted therapy. A different profile may favour immunotherapy or conventional chemo.
Having a biomarker does not automatically guarantee response, and lacking one does not mean there is no effective treatment. Results are interpreted in clinical context.
Who Benefits Most from Precision Approaches
Precision testing is especially valuable in cancers where approved targeted or immunotherapy options exist, in advanced disease needing systemic therapy, after progression on standard treatment, or when a rare/unusual cancer needs clearer classification.
Even in earlier stages, biomarker results can influence decisions—for example, HER2-directed therapy in breast cancer or mutation-informed choices in lung cancer.
Patients seeking a second opinion often benefit from a review of whether appropriate molecular testing was done and whether newer options apply.
Limits and Realistic Expectations
Precision oncology is powerful, but not magic. Some tumours have no currently actionable target. Access, cost, sample quality, and turnaround time can affect testing. A mutation listed on a report may not have an approved drug for that cancer type.
Clinical trials may be considered when an alteration is found but standard options are limited. Your oncologist can help separate established treatments from experimental ones.
The best plans combine biomarker data with stage, fitness, comorbidities, prior therapy, and patient preferences.
Questions to Ask Your Oncologist
Useful questions include: Which biomarkers matter for my cancer? Has testing already been done on my biopsy? Do I need additional molecular tests before starting treatment? Are there targeted therapy or immunotherapy options based on my results? How will side effects and monitoring differ?
Bring pathology reports, prior treatment records, and imaging summaries to the visit. Clear documentation speeds decision-making.
At Marengo Asia Hospitals, Gurugram, I help patients interpret reports and build personalised plans across solid tumours and blood cancers—using precision tools when they meaningfully change care.
Precision oncology matches treatment to tumour biology—ask which biomarkers matter for your cancer and how results change chemotherapy, targeted therapy, or immunotherapy choices.
अक्सर पूछे जाने वाले प्रश्न
No. It is often discussed in advanced disease, but biomarkers also guide treatment in earlier stages for several cancers, including certain breast and lung cancers.
Not always. Some decisions need only specific tests. NGS is useful when broader molecular profiling may open targeted options or when recommended for your cancer type and stage.
No. Many effective treatments do not depend on a single mutation. Standard chemotherapy, immunotherapy, hormonal therapy, surgery, or radiation may still be appropriate.
It varies by test and laboratory—from a few days for some IHC markers to one or more weeks for larger molecular panels. Your oncology team can explain expected timelines and whether treatment should start meanwhile.